Product logins

Find logins to all Clarivate products below.


Gastrointestinal Stromal Tumor, Malignant Melanoma, Renal Cell Carcinoma | Access and Reimbursement | EU5 | 2016

The success of an anticancer therapy is not only dependent on the outcome of its pivotal trial, but also on that trial’s design, which is examined by the regulatory bodies, payers, and prescribers. In our analysis, we assess the influence of trial design on treatment and reimbursement decisions regarding current and emerging therapies for malignant melanoma, renal cell carcinoma (RCC), and gastrointestinal stromal tumors (GIST). In addition, we explore payers’ and prescribers’ cost-sensitivity and preference for trial design features, such as primary end points and comparators.

Related Market Assessment Reports

Report
Eosinophilic Esophagitis – Unmet Need – Unmet Need – Eosinophilic Esophagitis (US/EU)
Standard treatments for eosinophilic esophagitis (EoE) typically include proton pump inhibitors (PPIs) and swallowed topical steroids. Although these therapies can alleviate EoE symptoms, their…
Report
Biosimilars – Forecast – Oncology
In 2024, sales of branded MAb biologics in oncology exceeded $48 billion in the major pharmaceutical markets (United States, EU5, and Japan), and sales of biosimilars totaled $5.9 billion…
Report
Crohn’s Disease – Landscape & Forecast – Disease Landscape & Forecast (G7)
The Crohn’s disease (CD) therapy market will grow steadily over the next 10 years as a result of the increasing use of biologics / targeted oral therapies. The well-established TNF-alpha…
Report
Malignant Melanoma – Landscape & Forecast – Disease Landscape & Forecast (G7)
The introduction of the immune checkpoint inhibitors Keytruda (Merck & Co.), Opdivo ± Yervoy, and Opdualag (Bristol Myers Squibb), as well as BRAF/MEK inhibitor combinations such as Roche /…
Report
Crohn’s Disease – Unmet Need – Unmet Need – Moderate to Severe Crohn’s Disease (US/EU)
Crohn’s disease (CD) is a chronic inflammatory bowel disorder characterized by diarrhea, abdominal pain, and weight loss. Tumor necrosis factor (TNF)-α inhibitors, such as Johnson & Johnson…